212 related articles for article (PubMed ID: 34448437)
21. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Huls G; Mulder AB; Rosati S; van de Loosdrecht AA; Vellenga E; de Wolf JT
Blood; 2010 Jul; 116(2):180-2. PubMed ID: 20194893
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution.
Hayama K; Abe Y; Kamata H; Okina S; Murakami Y; Kanoh Y; Suzuki T
Int J Hematol; 2022 Apr; 115(4):508-514. PubMed ID: 35064465
[TBL] [Abstract][Full Text] [Related]
24. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
25. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
26. [Concurrent CALR and SF3B1 gene mutations in a patient with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis].
Nakao K; Oka S; Utsumi T; Yamada S; Kondo T; Tohyama K; Asagoe K
Rinsho Ketsueki; 2019; 60(8):915-919. PubMed ID: 31484889
[TBL] [Abstract][Full Text] [Related]
27. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
[TBL] [Abstract][Full Text] [Related]
28. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
[No Abstract] [Full Text] [Related]
29. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
30. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
31. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
Gerke MB; Christodoulou I; Karantanos T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
[TBL] [Abstract][Full Text] [Related]
32. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
34. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
35. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
37. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
38. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome.
Alshaban A; Padilla O; Philipovskiy A; Corral J; McAlice M; Gaur S
Leuk Res Rep; 2018; 10():37-40. PubMed ID: 30186759
[TBL] [Abstract][Full Text] [Related]
40. Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis.
Kerneves P; Cornet E; Paubelle E
Int J Lab Hematol; 2021 Oct; 43(5):890-891. PubMed ID: 33586865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
